S0331: Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This phase II trial is studying how well imatinib mesylate works in treating patients with
metastatic or unresectable Merkel cell cancer. Imatinib mesylate may stop the growth of tumor
cells by blocking the enzymes necessary for tumor cell growth